NeuroEconSolutions (Neuroeconsolutions.com), Toronto, Canada.
Clinical Outcomes & Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronto, ON, Canada.
PLoS One. 2022 Feb 15;17(2):e0264006. doi: 10.1371/journal.pone.0264006. eCollection 2022.
The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals' treatment to therapeutic goals, disease progression, patient/caregiver's preferences, and personal experience to achieve an optimal risk/benefit balance. This study aims to provide insight into the preferred treatment choices of pediatric neurologists managing spinal muscular atrophy in their daily practice and to recognize behavioral factors that may influence decision-making.
This is a noninterventional, cross-sectional pilot study involving 50 pediatric neurologists managing spinal muscular atrophy in Spain. We designed an online platform that contains 13 simulated case scenarios of common presentations of patients with spinal muscular atrophy. The primary study outcome will be treatment preferences according to the percentages of participants who select treatment initiation when recommended, switch therapies when there is evidence of disease progression, and select treatment discontinuation when disease progression puts patients outside treatment recommendation (11 case scenarios). Secondary outcomes include therapeutic inertia prevalence (11 case scenarios), herding phenomenon prevalence (2 case scenarios), care-related regret prevalence (specific questions) and intensity (10-item Regret Intensity Scale), occupational burnout prevalence (nonproprietary single-item measure), and risk preferences (uncertainty test and risk aversion assessment).
The study findings will contribute to better understand relevant factors associated with therapeutic decisions of pediatric neurologists in spinal muscular atrophy, identifying treatment preferences and evaluating the role of behavioral aspects such as therapeutic inertia, herding, regret, and workplace burnout.
在过去的几年中,脊髓性肌萎缩症的治疗格局发生了变化,涵盖了呼吸/运动功能和预期寿命的获益。然而,医生仍然面临着将个体的治疗方案与治疗目标、疾病进展、患者/照顾者的偏好和个人经验相匹配的挑战,以实现最佳的风险/获益平衡。本研究旨在深入了解管理脊髓性肌萎缩症的儿科神经科医生在日常实践中的首选治疗选择,并认识可能影响决策的行为因素。
这是一项非干预性、横断面的初步研究,涉及 50 名在西班牙管理脊髓性肌萎缩症的儿科神经科医生。我们设计了一个在线平台,其中包含 13 个模拟病例场景,这些场景涉及脊髓性肌萎缩症患者的常见表现。主要研究结果将是根据推荐时选择治疗开始的参与者百分比、有疾病进展证据时选择转换治疗以及当疾病进展使患者超出治疗推荐范围时选择停止治疗的治疗偏好(11 个病例场景)。次要结果包括治疗惰性的流行程度(11 个病例场景)、羊群现象的流行程度(2 个病例场景)、与护理相关的后悔程度(特定问题)和强度(10 项后悔强度量表)、职业倦怠的流行程度(非专用单一项目测量)和风险偏好(不确定测试和风险厌恶评估)。
研究结果将有助于更好地了解与脊髓性肌萎缩症儿科神经科医生治疗决策相关的相关因素,确定治疗偏好,并评估行为方面(如治疗惰性、羊群现象、后悔和工作场所倦怠)的作用。